MTOR and breast cancer: In tamoxifen-resistant LCC2 and LCC9 breast cancer cell lines, rate of glycolysis is higher than that in MCF-7S cells, and HIF-1 was found to be activated through the Akt/mTOR signaling pathway, with phosphorylated AMPK being decreased without hypoxic conditions.